Catecholamine Drugs

Catecholamine drugs are sympathomimetic agents built on the catechol-amine structure — among them the endogenous transmitters norepinephrine, epinephrine, and dopamine, and the synthetic analogue dobutamine. They act on adrenergic and dopaminergic receptors to increase cardiac contractility and rate and to modulate vascular tone, and they are the prototypical positive inotropes used for acute circulatory support.

Definition

Catecholamines are compounds containing a catechol nucleus (a benzene ring with two adjacent hydroxyl groups) and an amine side chain; as drugs they act as agonists at adrenergic and/or dopaminergic receptors, producing dose- and subtype-dependent effects on the heart and blood vessels.

Scope

This topic covers the pharmacology of the catecholamine class: their shared chemical structure, the adrenergic and dopaminergic receptors through which they act, and how receptor selectivity translates into cardiac and vascular effects. It treats the class as a reference pharmacology topic and gives no dosing or individualized treatment guidance.

Core questions

• How does the catechol structure determine receptor binding and metabolism by catechol-O-methyltransferase and monoamine oxidase?
• How do the relative affinities of each catecholamine for alpha, beta-1, beta-2, and dopaminergic receptors explain their differing cardiovascular profiles?
• Why does sustained adrenergic stimulation lead to receptor desensitization and down-regulation in the failing heart?

Key concepts

• Catechol nucleus and amine side chain
• Beta-1 receptor stimulation and positive inotropy/chronotropy
• Alpha-1 mediated vasoconstriction and beta-2 mediated vasodilation
• Dopaminergic receptor effects
• Receptor desensitization and down-regulation
• Short half-life and metabolism by COMT and MAO

Mechanisms

Catecholamines bind G-protein-coupled adrenergic and dopaminergic receptors. Beta-1 stimulation activates Gs, raising cyclic AMP and protein kinase A activity, which increases calcium entry through L-type channels and accelerates calcium cycling, producing greater contractile force and faster heart rate. Alpha-1 stimulation drives vasoconstriction through Gq and phospholipase C, while beta-2 stimulation causes vasodilation. The balance of these affinities differs between agents — epinephrine engages alpha and beta receptors, norepinephrine is predominantly alpha and beta-1 with little beta-2, dopamine adds dopaminergic effects, and dobutamine is a relatively selective beta-1 agonist. The catechol structure makes these agents substrates for catechol-O-methyltransferase and monoamine oxidase, giving them a short duration of action. Chronic adrenergic drive, as in heart failure, leads to beta-receptor desensitization and down-regulation, limiting sustained benefit.

Clinical relevance

Catecholamines are the reference agents for understanding adrenergic pharmacology and acute haemodynamic support, and trials comparing them inform how the evidence base is read. The SOAP II trial, for example, compared dopamine and norepinephrine as first-line vasopressors in shock and is widely cited in the appraisal of these agents. This entry describes mechanisms and evidence and is not a basis for individual treatment decisions; it contains no dosing information.

Evidence & guidelines

The SOAP II randomized trial (De Backer and colleagues, 2010) is a key comparative study of dopamine versus norepinephrine in shock and is frequently referenced when these agents are discussed. Reviews of the adrenergic system in heart failure place the catecholamines within the broader pathophysiology of sympathetic activation. These sources are cited for orientation and not reproduced as recommendations.

History

The physiological actions of adrenal extracts were described around the turn of the twentieth century, and epinephrine was among the first hormones to be isolated and synthesized. Raymond Ahlquist's 1948 proposal of distinct alpha and beta adrenergic receptors gave a framework for understanding why different catecholamines produce different effects, and the later molecular cloning and characterization of adrenergic receptors refined that picture and explained subtype-selective drug action.

Debates

Which catecholamine is preferable as a first-line vasopressor in shock?

Comparative trial evidence raised concerns about arrhythmia with dopamine relative to norepinephrine, shifting the discussion toward norepinephrine in many settings, though the question remains context-dependent and is treated here only as an evidence-appraisal matter.

Key figures

• Raymond Ahlquist
• Robert Lefkowitz

Seminal works

• de-backer-2010
• lymperopoulos-2013

Frequently asked questions

What makes a drug a catecholamine?

Chemically, a catecholamine has a catechol ring (a benzene ring with two adjacent hydroxyl groups) plus an amine side chain. Norepinephrine, epinephrine, dopamine, and the synthetic dobutamine share this structure and act on adrenergic and dopaminergic receptors.

Why do catecholamines have such a short duration of action?

Their catechol structure makes them rapid substrates for the enzymes catechol-O-methyltransferase and monoamine oxidase, which break them down quickly, so their effects are brief and they are typically given by continuous infusion in acute care.